摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-溴-1-(2,6-二氟苯基)乙酮 | 56159-89-8

中文名称
2-溴-1-(2,6-二氟苯基)乙酮
中文别名
2,6-二氟溴苯乙酮;2-溴-2`,6`-二氟苯乙酮;2-溴-2',6'-二氟苯乙酮
英文名称
2-bromo-1-(2,6-difluorophenyl)ethanone
英文别名
2,6-difluorophenacyl bromide
2-溴-1-(2,6-二氟苯基)乙酮化学式
CAS
56159-89-8
化学式
C8H5BrF2O
mdl
MFCD04038255
分子量
235.028
InChiKey
UZKLFNHMBFDXEN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    234.0±25.0 °C(Predicted)
  • 密度:
    1.648±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    F,C
  • 海关编码:
    2914700090
  • 包装等级:
    II
  • 危险类别:
    8
  • 危险性防范说明:
    P260,P264,P270,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P405,P501
  • 危险品运输编号:
    3265
  • 危险性描述:
    H302,H314
  • 储存条件:
    室温且干燥环境下使用。

SDS

SDS:ea45e0d2da3c7b6ab3a4ac8251a18832
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Bromo-2’,6’-difluoroacetophenone
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-2’,6’-difluoroacetophenone
CAS number: 56159-89-8

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H5BrF2O
Molecular weight: 235

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-溴-1-(2,6-二氟苯基)乙酮四氢吡咯 、 ammonium acetate 、 三氟乙酸 作用下, 以 乙醇二氯甲烷 为溶剂, 反应 25.0h, 生成 2-(2,6-difluorophenyl)-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridine hydrochloride
    参考文献:
    名称:
    [EN] ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS
    [FR] PYRROLES CONDENSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE CRAC
    摘要:
    该发明涉及通式(I)的取代双环吡咯杂环基化合物,其中A1和A2代表直接键或C(=O),但A1和A2中的0或1个代表C(=O);m和n独立地表示0、1、2或3,但要求总和[n + m]为1、2、3或4;R1代表H、F、CI、Br、I、CN、CF3、CF2H、CFH2、CO2H、CO2R13、R13、OH、O-R13、NH2、N(H)R13、N(R13)2;R2表示0到4个取代基,每个独立地选自F、CI、Br、CN、CF3、CF2H、CFH2、R13、OH、O-R13、NH2、N(H)R13和N(R13)2;Ar1表示苯基或5-或6-成员杂芳基,每种情况下未取代或取代为一个、两个、三个或四个取代基,独立地选自F、CI、Br、CN、CF3、CF2H、CFH2、R13和O-R13;或C3-6-环烷基或3到7-成员杂环烷基,每种情况下未取代或单取代或多取代;Ar2表示苯基或5-或6-成员杂芳基,其中所述苯基或所述杂芳基可以未取代或单取代或多取代,并且可以与4-、5-、6-或7-成员环融合,为碳环或杂环,所述融合环可以饱和、部分不饱和或芳香,并且可以未取代或单取代或多取代;用作ICRAC抑制剂,用于含有这些化合物的药物组合物,以及用于治疗和/或预防疾病和/或疾病,特别是炎症性疾病和/或炎症性疾病的这些化合物。
    公开号:
    WO2015022073A1
  • 作为产物:
    描述:
    2,6-二氟苯乙酮三氯化铝 作用下, 以 氯仿 为溶剂, 生成 2-溴-1-(2,6-二氟苯基)乙酮
    参考文献:
    名称:
    噻吩作为生理活性物质的结构元素,第 4 手套。O-取代的 5-苯基-噻吩[2,3-e] [1,4] 二氮杂
    摘要:
    描述了标题化合物 13、15、16 和 17 的合成和药理学。
    DOI:
    10.1002/ardp.19803130704
点击查看最新优质反应信息

文献信息

  • Synthesis of novel amide and urea derivatives of thiazol-2-ethylamines and their activity against Trypanosoma brucei rhodesiense
    作者:Donald A. Patrick、Tanja Wenzler、Sihyung Yang、Patrick T. Weiser、Michael Zhuo Wang、Reto Brun、Richard R. Tidwell
    DOI:10.1016/j.bmc.2016.04.006
    日期:2016.6
    analogues were tested against T. brucei rhodesiense STIB900 and L6 rat myoblast cells (for cytotoxicity) in vitro. Forty-four derivatives were more potent than 1, including eight with IC50 values below 100 nM. The most potent and most selective for the parasite was the urea analogue 2-(2-piperidin-1-ylamido)ethyl-4-(3-fluorophenyl)thiazole (70, IC50 = 9 nM, SI > 18,000). None of 33 compounds tested were able
    2-(2-Benzamido)ethyl-4-phenylthiazole(1)是1035个分子(分为115个不同的支架)之一,被发现可抑制布氏锥虫(引起人类非洲锥虫病的病原体),浓度低于3.6μM,且非在由诺华研究基金会(GNF)的基因组学研究所进行的700,000种化合物库的表型高通量筛选中,对哺乳动物(Huh7)细胞具有毒性。在本实验室中,化合物1和72类似物是通过两种通用途径之一合成的。这些加10代市售的类似物进行了对所测试的T.布氏罗得西亚STIB900和体外大鼠L6成肌细胞(细胞毒性)。四十四个导数的强于一,其中八个IC 50值低于100 nM。对该寄生虫最有效和最具选择性的是尿素类似物2-(2-哌啶-1--1-基氨基)乙基-4-(3-氟苯基)噻唑(70,IC 50  = 9 nM,SI> 18,000)。测试的33种化合物中没有一种能够治愈被寄生虫感染的小鼠。但是,有7种化合
  • BENZOXAZINE DERIVATIVES AS CRAC MODULATORS
    申请人:Hoffmann-La Roche Inc.
    公开号:US20130090333A1
    公开(公告)日:2013-04-11
    Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).
    公式(I)的化合物: 或其药用可接受的盐,其中R1和R2如本文所述定义。还公开了制造这些化合物的方法以及使用这些化合物治疗与钙释放激活钙通道(CRAC)相关疾病的用途。
  • AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS
    申请人:Hoffmann-La Roche Inc
    公开号:US20130090334A1
    公开(公告)日:2013-04-11
    Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).
    公式(I)的化合物: 或其药用可接受的盐,其中R1和R2如本文所述定义。还公开了制造这些化合物的方法以及使用这些化合物治疗与钙释放激活钙通道(CRAC)相关疾病的用途。
  • TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    申请人:Incyte Corporation
    公开号:US20210171535A1
    公开(公告)日:2021-06-10
    The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    本公开涉及三环杂环化合物及其药物组合物,这些化合物是FGFR酶的抑制剂,可用于治疗FGFR相关疾病,如癌症。
  • High Chemo-/Stereoselectivity for Synthesis of Polysubstituted Monofluorinated Pyrimidyl Enol Ether Derivatives
    作者:Lei Kang、Fang Wang、Jinlong Zhang、Huameng Yang、Chungu Xia、Jinlong Qian、Gaoxi Jiang
    DOI:10.1021/acs.orglett.1c00092
    日期:2021.3.5
    A novel intramolecular Smiles rearrangement of α-fluoro-β-keto-pyrimidylsulfones (usually used as a carbon nucleophile) was developed, providing a versatile avenue for synthesis of tri/tetra-substituted monofluorinated pyrimidyl enol ethers. Among these, diverse (Z)-monofluorovinylsulfones and sulfinates were efficiently assembled by adding extra electrophile and fine-tuning reaction conditions. The
    开发了新型的α-氟-β-酮-嘧啶基砜的分子内Smiles重排(通常用作碳亲核试剂),为合成三/四取代的单氟嘧啶基烯醇醚提供了多方面的途径。其中,通过添加额外的亲电试剂和微调反应条件,可以有效地组装各种(Z)-单氟乙烯基砜和亚磺酸盐。从烯醇氧阴离子到嘧啶2-碳的酮-烯醇互变异构现象触发了这一过程,这与经典的碳亲核加成反应方法完全不同。
查看更多